<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Intern Med</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2168-6106</issn><issn pub-type="epub">2168-6114</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10804281</article-id><article-id pub-id-type="pmcid-ver">PMC10804281.1</article-id><article-id pub-id-type="pmcaid">10804281</article-id><article-id pub-id-type="pmcaiid">10804281</article-id><article-id pub-id-type="pmid">38252426</article-id><article-id pub-id-type="doi">10.1001/jamainternmed.2023.6986</article-id><article-id pub-id-type="publisher-id">ioi230085</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="featured" specific-use="electronic"><subject>Featured</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group></article-categories><title-group><article-title>First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations</article-title><alt-title alt-title-type="headline">First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations</alt-title><alt-title alt-title-type="running-head">First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Suarez</surname><given-names initials="EA">Elizabeth A.</given-names></name><degrees>PhD</degrees><degrees>MPH</degrees><xref rid="ioi230085aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ioi230085aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ioi230085aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bateman</surname><given-names initials="BT">Brian T.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="ioi230085aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Straub</surname><given-names initials="L">Loreen</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="ioi230085aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hern&#225;ndez-D&#237;az</surname><given-names initials="S">Sonia</given-names></name><degrees>MD</degrees><degrees>DrPH</degrees><xref rid="ioi230085aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="HE">Hendr&#233;e E.</given-names></name><degrees>PhD</degrees><xref rid="ioi230085aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gray</surname><given-names initials="KJ">Kathryn J.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="ioi230085aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Connery</surname><given-names initials="HS">Hilary S.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="ioi230085aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="ioi230085aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davis</surname><given-names initials="JM">Jonathan M.</given-names></name><degrees>MD</degrees><xref rid="ioi230085aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lester</surname><given-names initials="B">Barry</given-names></name><degrees>PhD</degrees><xref rid="ioi230085aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Terplan</surname><given-names initials="M">Mishka</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="ioi230085aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yanmin</given-names></name><degrees>PhD</degrees><degrees>MS</degrees><xref rid="ioi230085aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vine</surname><given-names initials="SM">Seanna M.</given-names></name><degrees>MPH</degrees><xref rid="ioi230085aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mogun</surname><given-names initials="H">Helen</given-names></name><degrees>MS</degrees><xref rid="ioi230085aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huybrechts</surname><given-names initials="KF">Krista F.</given-names></name><degrees>MS</degrees><degrees>PhD</degrees><xref rid="ioi230085aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="ioi230085aff1"><label>1</label>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women&#8217;s Hospital and Harvard Medical School, Boston, Massachusetts</aff><aff id="ioi230085aff2"><label>2</label>Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey</aff><aff id="ioi230085aff3"><label>3</label>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey</aff><aff id="ioi230085aff4"><label>4</label>Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California</aff><aff id="ioi230085aff5"><label>5</label>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts</aff><aff id="ioi230085aff6"><label>6</label>UNC Horizons Program, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill</aff><aff id="ioi230085aff7"><label>7</label>Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women&#8217;s Hospital, Boston, Massachusetts</aff><aff id="ioi230085aff8"><label>8</label>Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts</aff><aff id="ioi230085aff9"><label>9</label>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts</aff><aff id="ioi230085aff10"><label>10</label>Department of Pediatrics, Tufts Medical Center and the Tufts Clinical and Translational Science Institute, Boston, Massachusetts</aff><aff id="ioi230085aff11"><label>11</label>Center for the Study of Children at Risk, Departments of Psychiatry and Pediatrics, Alpert Medical School of Brown University and Women and Infants Hospital, Providence, Rhode Island</aff><aff id="ioi230085aff12"><label>12</label>Friends Research Institute, Baltimore, Maryland</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> September 12, 2023.</p><p content-type="published-online"><bold>Published Online:</bold> January 22, 2024. doi:<uri content-type="doi">10.1001/jamainternmed.2023.6986</uri></p><p content-type="correction-note"><bold>Correction: </bold>This article was corrected on July 1, 2024, to fix an error in Figure 1.</p><corresp id="ioi230085cor1"><bold>Corresponding Author:</bold> Elizabeth A. Suarez, PhD, MPH, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women&#8217;s Hospital and Harvard Medical School, 1620 Tremont St, Ste 3030, Boston, MA 02120 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="h4p@bwh.harvard.edu">h4p@bwh.harvard.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Suarez and Huybrechts had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Suarez, Bateman, Straub, Hern&#225;ndez-D&#237;az, Jones, Terplan, Huybrechts.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Suarez, Jones.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> Suarez, Straub, Vine, Mogun.</p><p><italic toggle="yes">Obtained funding:</italic> Bateman, Hern&#225;ndez-D&#237;az, Huybrechts.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Suarez, Bateman, Straub, Hern&#225;ndez-D&#237;az, Davis, Lester, Terplan, Zhu, Huybrechts.</p><p><italic toggle="yes">Supervision:</italic> Bateman, Gray, Davis, Huybrechts.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Hern&#225;ndez-D&#237;az reported grants from Takeda to her institution for unrelated work, personal fees from Janssen and Moderna for methods consulting for unrelated work, and payment from UCB as a consultant for unrelated work. Dr Gray reported serving as a consultant for BillionToOne, Aetion, Illumina, and Roche outside of the scope of the submitted work. Dr Connery reported work as a consultant for Alosa Health. Dr Zhu reported grants from Takeda Pharmaceutical Company outside the submitted work. Dr Huybrechts reported grants from UCB and Takeda to her institution outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by the National Institute on Drug Abuse (No. R01 DA049822).</p><p><bold>Role of the Funder/Sponsor:</bold> The National Institute on Drug Abuse had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Meeting Presentation:</bold> This work was presented at the 37th International Conference on Pharmacoepidemiology; August 25, 2021; virtual event.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-IOI230085-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-01-22T10:00"><day>22</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2024</year></pub-date><pub-date pub-type="ecorrected"><day>1</day><month>7</month><year>2024</year></pub-date><volume>184</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">453953</issue-id><fpage>242</fpage><lpage>251</lpage><history><date date-type="received"><day>19</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>9</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>22</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-22 00:25:14.757"><day>22</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamainternmed-e236986.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamainternmed-e236986.pdf">jamainternmed-e236986.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archinte/fullarticle/10.1001/jamainternmed.2023.6986"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" journal-id="JAMA Intern Med" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11217882"><article-title>Error in Figure 1</article-title><volume>184</volume><issue>8</issue><date><day>1</day><month>7</month><year>2024</year></date><fpage>993</fpage><lpage>993</lpage><source>JAMA Internal Medicine</source><pub-id pub-id-type="doi">10.1001/jamainternmed.2024.3261</pub-id><pub-id pub-id-type="pmcid">PMC11217882</pub-id><pub-id pub-id-type="pmid">38949833</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" journal-id="JAMA Intern Med" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="38252422"><article-title>The Importance of Treating Opioid Use Disorder in Pregnancy.</article-title><date><day>22</day><month>1</month><year>2024</year></date><source>JAMA Intern Med</source><pub-id pub-id-type="doi">10.1001/jamainternmed.2023.7272</pub-id><pub-id pub-id-type="pmid">38252422</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" journal-id="JAMA Intern Med" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="38252420"><article-title>Prenatal Opioid Use Disorder Treatment-the Importance of Shared Decision-Making.</article-title><date><day>22</day><month>1</month><year>2024</year></date><source>JAMA Intern Med</source><pub-id pub-id-type="doi">10.1001/jamainternmed.2023.6976</pub-id><pub-id pub-id-type="pmid">38252420</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" journal-id="JAMA Intern Med" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="38252452"><article-title>Medication for the Treatment of Opioid Use Disorder in Pregnancy Is Essential.</article-title><date><day>22</day><month>1</month><year>2024</year></date><source>JAMA Intern Med</source><pub-id pub-id-type="doi">10.1001/jamainternmed.2023.6977</pub-id><pub-id pub-id-type="pmid">38252452</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" journal-id="JAMA" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="38294782"><article-title>Buprenorphine Treatment May Be Safer than Methadone During Pregnancy.</article-title><date><day>31</day><month>1</month><year>2024</year></date><source>JAMA</source><pub-id pub-id-type="doi">10.1001/jama.2023.28344</pub-id><pub-id pub-id-type="pmid">38294782</pub-id></related-article><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study compares the risk of congenital malformations among infants following in utero exposure to buprenorphine vs methadone.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-ioi230085-1"><title>Question</title><p>Does the risk of congenital malformations differ among infants following in utero exposure to buprenorphine or methadone for treatment of opioid use disorder in pregnancy?</p></sec><sec id="ab-ioi230085-2"><title>Findings</title><p>In this cohort study of 9514 pregnancies with first-trimester buprenorphine exposure and 3846 with methadone exposure, the prevalence of congenital malformations overall and several malformation subtypes was lower among pregnant individuals treated with buprenorphine compared with methadone, except for gastrointestinal malformations. There was an 18% relative risk reduction for malformations overall, which translates to 1 less event per 100 patients treated with buprenorphine vs methadone.</p></sec><sec id="ab-ioi230085-3"><title>Meaning</title><p>When determining optimal treatment for pregnant individuals with opioid use disorder, considerations should include the relative risk reduction for malformations overall with buprenorphine vs methadone, as well as treatment access, previous success on a particular treatment, and the likelihood of retention in treatment.</p></sec></abstract><abstract><sec id="ab-ioi230085-4"><title>Importance</title><p>Use of buprenorphine or methadone to treat opioid use disorder is recommended in pregnancy; however, their teratogenic potential is largely unknown.</p></sec><sec id="ab-ioi230085-5"><title>Objective</title><p>To compare the risk of congenital malformations following in utero exposure to buprenorphine vs methadone.</p></sec><sec id="ab-ioi230085-6"><title>Design, Setting, and Participants</title><p>This population-based cohort study used health care utilization data from publicly insured Medicaid beneficiaries in the US from 2000 to 2018. A total of 13&#8201;360 pregnancies with enrollment from 90 days prior to pregnancy start through 1 month after delivery and first trimester use of buprenorphine or methadone were included and linked to infants. Data were analyzed from July to December 2022.</p></sec><sec id="ab-ioi230085-7"><title>Exposure</title><p>A pharmacy dispensing of buprenorphine or a code for administration of methadone in the first trimester.</p></sec><sec id="ab-ioi230085-8"><title>Main Outcomes and Measures</title><p>Primary outcomes included major malformations overall and malformations previously associated with opioids (any cardiac malformations, ventricular septal defect, secundum atrial septal defect/nonprematurity-related patent foramen ovale, neural tube defects, clubfoot, and oral clefts). Secondary outcomes included other organ system&#8211;specific malformations. Risk differences and risk ratios (RRs) were estimated comparing buprenorphine with methadone, adjusting for confounders with propensity score overlap weights.</p></sec><sec id="ab-ioi230085-9"><title>Results</title><p>The cohort included 9514 pregnancies with first-trimester buprenorphine exposure (mean [SD] maternal age, 28.4 [4.6] years) and 3846 with methadone exposure (mean [SD] maternal age, 28.8 [4.7] years). The risk of malformations overall was 50.9 (95% CI, 46.5-55.3) per 1000 pregnancies for buprenorphine and 60.6 (95% CI, 53.0-68.1) per 1000 pregnancies for methadone. After confounding adjustment, buprenorphine was associated with a lower risk of malformations compared with methadone (RR, 0.82; 95% CI, 0.69-0.97). Risk was lower with buprenorphine for cardiac malformations (RR, 0.63; 95% CI, 0.47-0.85), including both ventricular septal defect (RR, 0.62; 95% CI, 0.39-0.98) and secundum atrial septal defect/nonprematurity-related patent foramen ovale (RR, 0.54; 95% CI, 0.30-0.97), oral clefts (RR, 0.65; 95% CI, 0.35-1.19), and clubfoot (RR, 0.55; 95% CI, 0.32-0.94). Results for neural tube defects were uncertain given low event counts. In secondary analyses, buprenorphine was associated with a decreased risk of central nervous system, urinary, and limb malformations but a greater risk of gastrointestinal malformations compared with methadone. These findings were consistent in sensitivity and bias analyses.</p></sec><sec id="ab-ioi230085-10"><title>Conclusions and Relevance</title><p>In this cohort study, the risk of most malformations previously associated with opioid exposure was lower in buprenorphine-exposed infants compared with methadone-exposed infants, independent of measured confounders. Malformation risk is one factor that informs the individualized patient decision regarding medications for opioid use disorder in pregnancy.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>